These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16699903)

  • 1. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
    Papp KA; Camisa C; Stone SP; Caro I; Wang X; Compton P; Walicke PA; Gottlieb AB
    J Cutan Med Surg; 2005 Dec; 9(6):313-23. PubMed ID: 16699903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
    Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
    Pariser DM; Gordon KB; Papp KA; Leonardi CL; Kwon P; Compton PG; Rundle AC; Walicke PA; Lebwohl M
    J Cutan Med Surg; 2005 Dec; 9(6):303-12. PubMed ID: 16699904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
    Hamilton T; Menter A; Caro I; Compton P; Sobell J; Papp KA
    Drug Saf; 2008; 31(8):715-26. PubMed ID: 18636790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
    Gottlieb AB; Miller B; Lowe N; Shapiro W; Hudson C; Bright R; Ling M; Magee A; McCall CO; Rist T; Dummer W; Walicke P; Bauer RJ; White M; Garovoy M
    J Cutan Med Surg; 2003; 7(3):198-207. PubMed ID: 12717587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab.
    Pincelli C; Henninger E; Casset-Semanaz F
    Arch Dermatol Res; 2006 Dec; 298(7):329-38. PubMed ID: 17021768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts and review of efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efalizumab: a review of events reported during clinical trials and side effects.
    Scheinfeld N
    Expert Opin Drug Saf; 2006 Mar; 5(2):197-209. PubMed ID: 16503742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
    Toth DP; Papp K; Gratton D
    Dermatol Ther; 2008; 21 Suppl 3():S6-14. PubMed ID: 19076630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.